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Abstract 
 
Background: Schistosomiasis is a neglected tropical disease that affects millions of people worldwide. 
Thioredoxin glutathione reductase of Schistosoma mansoni (SmTGR) is a validated drug target that plays 
a crucial role in the redox homeostasis of the parasite. We report the discovery of new chemical scaffolds 
against S. mansoni using a combi-QSAR approach followed by virtual screening of a commercial database 
and confirmation of top ranking compounds by in vitro experimental evaluation with automated imaging 
of schistosomula and adult worms. 
Results: We constructed 2D and 3D quantitative structure–activity relationship (QSAR) models using a 
series of oxadiazoles-2-oxides reported in the literature as SmTGR inhibitors and combined the best 
models in a consensus QSAR model. This model was used in a virtual screen of a commercial database 
and allowed the identification of ten new potential SmTGR inhibitors. The latter were screened on 
schistosomula and two active compounds were further evaluated on adult worms. Conclusions: We 
succeed to develop predictive virtual screening tool based on 2D and 3D QSAR models. After prioritizing 
virtual screening hits, high activity of two compounds representing new chemical scaffolds, 4-nitro-3,5-
bis(1-nitro-1H-pyrazol-4-yl)-1H-pyrazole and 3-nitro-4-{[(4-nitro-1,2,5-oxadiazol-3-yl)oxy]methyl}-
1,2,5-oxadiazole (LabMol-17 and LabMol-19, respectively) was experimentally validated. These 
compounds will be subjects for additional testing and, if necessary, modification to serve as new 
schistosomicidal agents. 
 
Defined key terms 
Hologram quantitative structure-activity relationship (HQSAR): 2D quantitative structure-activity 
relationship (QSAR) approach based on a special type of structural fingerprints, also known as a molecular 
hologram, where information is used as an independent variable during calculations.      
 
Comparative molecular field analysis (CoMFA): 3D QSAR approach based on the calculation of 
molecular interaction fields between aligned molecules and a defined probe atom placed in different 
intersections of a lattice box. It uses the principle that most ligand-target interactions are noncovalent and 
can be described by steric and electrostatic fields.  
 
Comparative molecular similarity indices analysis (CoMSIA): 3D QSAR approach based on the 
calculation of molecular similarity indices between aligned molecules and a probe atom placed in different 
intersections of a lattice box. In addition to steric and electrostatic fields, it calculates hydrophobic, H-
bond donor and acceptor fields.  
 
High content screening: A high-throughput phenotypic screening approach relying on automated 
microscopy followed by multiparametric computational image analysis. 
 
 
 
Introduction 
Schistosomiasis is one of the major neglected tropical diseases (NTDs) that affects millions of 
people worldwide [1]. Recent estimates suggest that at least 261 million people required preventive 
treatment for this disease in 2013. This parasitosis is reported in 78 countries located in sub-Saharan 
Africa, the Middle East, the Caribbean, and South America, resulting in 20,000 to 200,000 deaths 
annually [2]. The disease is caused by flatworms of the genus Schistosoma (S. mansoni, S. 
japonicum, S. haematobium, S. intercalatum, and S. mekongi)  [3,4]. In the absence of a vaccine, 
praziquantel (PZQ) has been the drug of choice recommended by the World Health Organization 
for the treatment and control of all the major Schistosoma species in mass drug administration 
programs for almost three decades [5]. However, the disseminated and repeated use of this drug in 
endemic areas, because of the high incidence of reinfection, brings concerns about the development 
of parasitic resistance [6,7]. This problem is further emphasized by the known lack of efficacy of 
PZQ against juvenile worms [8], which is a potential cause of treatment failure in endemic areas. 
For these reasons, the development of new schistosomicidal drugs is urgently required [6–10].   
The complete genome sequencing of S. mansoni has brought the possibility of exploring a great variety 
of biological targets in the search for new drugs against this parasite [11,12]. Thioredoxin glutathione 
reductase of S. mansoni (SmTGR, E.C. 1.8.1.9) plays a crucial role in the redox homeostasis of the parasite 
[13]. SmTGR is a multifunctional enzyme that acts in the detoxification of reactive oxygen species (ROS) 
present in the blood vessels of the mammalian host, thus allowing parasite survival. While mammalian 
cells use several enzymes of the glutathione and thioredoxin systems, S. mansoni ROS detoxification relies 
only on SmTGR [13,14]. Moreover, it has been validated as a potential drug target as demonstrated in 
studies silencing SmTGR expression using RNA interference [13]. Validation studies have also been 
performed in S. japonicum, confirming the importance of TGR in parasite survival [15,16]. 
Advances in computational hardware and software over the last few decades have enabled the 
development of new strategies for computer-aided/assisted drug design (CADD), which has the 
advantages of reducing the time and costs in the identification of new drug candidates [17–20]. 
Quantitative structure-activity relationship (QSAR) has been widely-used as a lead optimization tools as 
well as for pharmacokinetics property optimization and in virtual screening campaigns [21,22]. Our group 
has been working on developing and applying many CADD strategies aiming at discovering new drug 
candidates for neglected tropical diseases [23–35]. Another important technological advance impacting 
drug discovery was the introduction of automated microscopes along with powerful image analysis 
software enabling high-throughput phenotypic assays of cells and small organisms, a technique known as 
high-content screening (HCS), imaging (HCI) or analysis (HCA) [36]. Whole-organism antihelminthic 
screens employing the HCS approach have already proved useful for the larval stage of S. mansoni [37]. 
In this work, we report the discovery of two new antischistosomal chemical scaffolds by a combi-QSAR 
approach, using 2D- and 3D-QSAR models, followed by virtual screening of a commercial database and 
experimental evaluation of the potential SmTGR inhibitors against schistosomula and adult lifecycle 
stages of S. mansoni. For the latter we present a new medium-throughput assay methodology using 96-
well microplate and HCI technology. The general workflow of the study is presented in Figure 1. 
Materials & Methods 
Dataset  
The QSAR studies were performed using a series of 35 oxadiazoles-2-oxides reported in the literature 
as inhibitors of SmTGR whose in vitro enzymatic potency values (measured by IC50) were obtained by the 
same experimental protocol [38,39]. The IC50 values were converted to negative logarithmic units, pIC50 
(-log IC50) and used as dependent variables in the QSAR analysis. The pIC50 values span an approximate 
range of three orders of magnitude. The dataset was manually divided into training and test sets, ensuring 
a representative coverage across the entire range of pIC50 values. The training set was used to generate the 
QSAR models and the test set was used for external validation. The chemical structures and corresponding 
IC50 and pIC50 values are listed in Table 1. 
The 3D structures of the compounds were generated using OMEGA software v.2.5.1.4 [40,41]. 
OMEGA generates various initial conformations for each compound based on a database of pre-calculated 
fragments and the structures are optimized by MMFF94 force field. All QSAR models were generated 
and analyzed using SYBYL-X software v.1.2 [42]. 
 
Figure 1. Flowchart summarizing the workflow of this work. 
 
 
2D-QSAR 
HQSAR 
The HQSAR module available at SYBYL-X software v.1.2 [42] was used to HQSAR models 
generation. The initial models were derived using the standard fragment size (4-7 atoms) and various 
combinations of fragment distinctions. The models with q2LOO > 0.5 were used to predict the activity of 
all compounds of the dataset. 
 
 
 
 
Table 1. Chemical structures and corresponding IC50 and pIC50 experimental values of SmTGR inhibitors.  
Cpd  Structure R X IC50 (M) pIC50 
1 
 
CN - 6.30 5.20 
2 CH3 - 50.1 4.30 
3 CH2OH - 11.2 4.95 
 4a CHO - 0.11 6.95 
5 COOH - 0.63 6.20 
 6a CONH2 - 17.7 4.75 
7  
 
 
 
 
 
 
3-NO2 - 2.23 5.65 
8 3-CF3 - 2.51 5.60 
9 3-Br, 4-F - 2.81 5.55 
 10* 3-Br - 2.81 5.55 
11 3-Cl - 3.54 5.45 
12 4-Br - 3.54 5.45 
 13* 4-Cl - 4.07 5.39 
14 4-CF3 - 7.07 5.15 
15 3-OH - 7.07 5.15 
 16* 4-F - 7.94 5.10 
17 2-OMe - 7.94 5.10 
18 3,4,5-OMe - 8.91 5.05 
 19* 3-OMe - 8.91 5.05 
20 4-OMe - 10.0 5.00 
21 4-Me - 11.2 4.95 
22 4-Ph - 15.8 4.80 
23 4-OH - 18.1 4.74 
 
 
 
24 
 
 
 
 
 
- 
 
 
- 
 
 
0.04 
 
 
7.39 
 
 25* 
 
 
O 
 
- 
 
2.81 
 
5.55 
 
26 
 
S 
 
- 
 
3.54 
 
5.45 
 
27 
 
 
 
- 
 
 
- 
 
 
0.063 
 
 
7.20 
28  
 
 
 
 
- 1,3-Ph 3.54 5.45 
29 - 1,4-Ph 1.00 6.00 
30 - 5-F-1,3-Ph 0.47 6.32 
31 - 2,5-tiophene 0.40 6.39 
 32* - 2,4-tiophene 0.35 6.45 
 
33 
 
 
- 
 
- 
 
0.038 
 
7.42 
 34 
 
 
- 
 
- 
 
1.28 
 
5.89 
 
 35* 
 
 
 
 
- 
 
- 
 
0.10 
 
6.98 
Cpd= compound; * Test set compounds; a outliers. 
 
The final HQSAR models, after the division into training and test sets, were obtained using 
combinations of different fragment distinctions (A, atoms; B, bonds; C, connectivity; H, hydrogen; DA, 
donor and acceptors of hydrogen bonds), fragment size (2-5, 3-6, 4-7, 5-8, 6-9, 7-10 atoms) and hologram 
length (53-401). The partial least squares regression (PLS) [43–45] was performed to correlate the 
information coded in the molecular holograms with biological activity. 
3D-QSAR 
Atomic charges assignment 
Two different charge assignment methods were tested, the empirical method Gasteiger-Hückel [46,47], 
available at SYBYL-X v.1.2 platform [42] and the semi-empirical AM1-BCC charges [48,49] available 
at QUACPAC software v.1.6.3.1 [50]. 
Molecular alignment  
The shape-based alignment and alignment based on a morphological similarity function were 
evaluated. The former was performed using ROCS software v.3.2.1.4 [51,52]. First, several conformers 
were calculated for each molecule in OMEGA v.2.5.1.4 [40,41], which generated various initial 
conformations obtained from a database of pre-calculated fragments. Then, the conformers were 
superimposed, using ROCS, with the most potent SmTGR inhibitor (33). The conformers were classified 
according to the TanimotoCombo score function [52]. The alignment based on morphological similarity 
function was done in Surflex-Sim, available at SYBYL-X v.1.2 [42]. Two most potent SmTGR inhibitors, 
compounds 24 and 33, were chosen for template definition. Remaining compounds were superimposed 
with this template. The maximal number of poses generated per molecule was 20. The best pose of each 
compound was chosen based on the calculated similarity to the template. 
CoMFA 
The aligned training set molecules were placed in a 3D lattice box, with a grid spacing of 0.5, 1.0, 1.5 
and 2.0 Å in the x, y, and z directions. CoMFA steric and electrostatic fields were calculated at each grid 
point with the Tripos force field using a carbon atom probe with sp3 hybridization (Csp3) and charge +1.0. 
The energy cutoff was set to 30 kcal/mol. The standard deviation coefficients (SDC) were used for region 
focusing, with values ranging from 0.3 to 1.5. The calculated electrostatic and steric fields were correlated 
with biological activity by PLS regression. 
CoMSIA 
CoMSIA models were generated using the same molecular alignments used for CoMFA. The aligned 
compounds were placed in a 3D lattice box, with a grid spacing of 2.0 Å. In addition to the steric and 
electrostatic fields, hydrophobic, hydrogen bond donor and acceptor descriptors were included in CoMSIA 
studies. A probe carbon atom with radius of 1.0 Å and charge +1.0 was used for obtaining the similarity 
indices. A Gaussian function was used to describe the energetic terms in function of the distance between 
the probe atom and the aligned molecules with an attenuation factor of 0.3. 
QSAR model validation 
The internal validation of the QSAR models was performed to evaluate their robustness, using the full 
cross-validation r2 (q2), leave-one-out (LOO) and leave-many-out (LMO) methods. The latter was used to 
evaluate the stability of the best models and was performed using five groups and 25 runs.  
The predictive ability of the models was assessed by the correlation coefficient of prediction Q2ext, using 
the Q2F3 equation (Eq. 1) and the variants of the modified r
2 (rm
2): rm
2
(average) and rm
2
(delta) [53–55] (Eq. 2 
and 3) . 
 
 
 
 
In Eq. 1,  represents the predicted biological activity;  is the experimental biological 
activity;  is the mean of the biological activity for training set; nEXT is the number of compounds in 
test set; nTR is the number of compounds in training set. In Eqs. 2 and 3, rm
2 is the calculated modified r2 
and r’m 2 is the modified r2 after the inversion of x and y axes of the plot for experimental versus predicted 
biological activities. 
Consensus models 
Four consensus models were generated using different combinations of the best HQSAR, CoMFA and 
CoMSIA models. The predicted activity of each compound was the arithmetic mean of individual models 
predictions. The external validation of these models was done using the same metrics applied in individual 
models. Moreover, three other metrics were calculated for consensus models: root mean square error of 
calibration (RMSEC), root mean square error of prediction (RMSEP) and Durbin-Watson test (d). These 
metrics are described elsewhere [56–60]. 
Virtual screening of new potential SmTGR inhibitors 
The virtual screening of potential SmTGR inhibitors was performed based on similarity and common 
substructure search in the ChemBridge database [61]. First, the most potent inhibitor of the dataset (33) 
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was used as a template for the similarity search. Compounds with Tanimoto coefficient (Tc ≥ 0.6) were 
selected. Additionally, the substructure search was applied to find compounds containing the common 
substructure, i.e., the oxadiazole ring. All compounds were prepared using the same protocol and software 
used in QSAR dataset preparation, i.e., 3D structure and conformer generation, partial atomic charges 
calculation and molecular alignment. The chosen method of alignment and partial charges calculation was 
the same of the best individual CoMFA and CoMSIA models. In the next step, the best consensus model 
was used to predict the biological activity of the potential SmTGR inhibitors. The most promising 
compounds, with highest predicted pIC50, were selected for biological evaluation. Furthermore, five 
highly-predictive in-house models, described elsewhere [26,27], were used to predict some ADME 
properties of the compounds, such as logP, Caco-2 cell permeability, blood-brain barrier penetration 
(BBBP), hERG inhibition, CYP3A4 inhibition and water solubility. 
Biological evaluation on S. mansoni  
Compounds and Media 
Ten selected compounds were purchased from ChemBridge (San Diego-CA, USA) and given the 
identifiers LabMol-13 to LabMol-22. Compounds were resuspended in 100% DMSO and used 
immediately in the assays. DMEM and M169 media were purchased from Vitrocell (Campinas-SP, 
Brazil). All other reagents were purchased from Sigma-Aldrich (St. Louis-MO, USA). 
Larval Schistosoma mansoni (schistosomula) in vitro assay 
Schistosomula were produced by the mechanical method adapted from both Mansour et al. (2010) [62] 
and Marxer et al. (2012) [63]. The cercarie (S. mansoni, BH strain) were vortexed at maximum speed for 
5 minutes for tail shedding and cercarie transformation into schistosomula. The schistosomula were 
resuspended in Medium 169, plated in 384 well plates (120 per well) and maintained in an incubator with 
5% CO2 overnight before compound addition. Schistosomula were divided into three groups: negative 
control (0.625% DMSO), positive control (10 µM of PZQ or Oltipraz (OLT)) and treated (LabMol 
compounds at a concentration range of 0.3125-20 µM). The effect of the compounds on schistosomula 
motility and phenotypes was assessed at 48h after compound addition using an automated analysis method 
described below. 
Automated scoring of schistosomula motility and phenotype 
The automated image-based method for scoring schistosomula motility and phenotype was performed 
as described previously [64]. Bright-field images were collected using an ImageXpressMicro HCS 
microscope (IXM; Molecular Devices, Wokingham, UK). For motility analysis 5 x 6 sec interval time-
lapse images were collected using a 4x objective. For detailed morphology a 10x objective was used to 
collect 4 adjacent images fields from within a well, which were considered together to maximize larval 
numbers for phenotype analysis. Analysis of both the larval phenotype and motility was then carried out 
in Pipeline Pilot 9 as described by Paveley et al. (2012) [64]. Phenotype analysis of individual parasites 
was carried out by a two class Laplacian-modified Bayesian categorization model analysis of 80 image 
descriptors which constituted shape, size, image intensity and texture statistics and compared to a training 
set of data comprising 20,000 parasites.  Motility analysis of individual parasites was also analyzed by the 
average object displacement from the origin point in subsequent 4x image across the time-frame series. 
Both the Baeysian phenotype and motility scores are subsequently adjusted to the control wells (DMSO 
treated) on each plate [64].   
Adult Schistosoma mansoni ex vivo assays 
Three- to six-days old Swiss mice were individually infected percutaneously with 150 ± 10 S. mansoni 
cercariae (BH strain). The animals were placed into cylindrical vials under incandescent light with a thin 
water layer containing the cercariae for a period of 30 min. At 42-49 days after infection (i.e., the time 
required for S. mansoni to reach maturity), the animals were euthanized, and the worms were perfused 
(with 0.85% sodium chloride and 0.75% sodium citrate solution) from mesenteric and portal hepatic veins. 
Worms were rinsed and individually transferred into 96 well plates with complete DMEM media (i.e. 
DMEM plus 10% fetal calf serum, 2mM L-glutamine, 100 µM/ml penicillin, 100 µg/ml streptomycin). 
Male and female worms were distributed in three groups of six individuals each: negative control (0.02% 
DMSO), positive control (10 µM PZQ) and treatment (10 µM LabMol compounds). The plates were 
maintained at 37 °C in a humidified atmosphere of 5% CO2 throughout the entire experiment. The effect 
of the compounds on adult worm motility was assessed either immediately or 24, 48 or 72h after compound 
addition using the automated analysis method described below. 
Automated measurement of adult worm mobility 
Our strategy was based on sequential pairwise comparison of 100 time-lapse images captured every 
250-300 ms using an automated bright-field microscope with a 2x objective lens (ImageXpress Micro 
XLS, Molecular Devices, CA). Subsequent quantitative image analysis used a custom-developed pipeline 
for detecting changes in parasite motility using the open-source CellProfiler software version 2.1.2 [65]. 
The pipeline along with its validation will be thoroughly described in a subsequent publication and the 
pipeline itself will be made freely available.  Briefly, at each cycle of the pipeline, an image captured at a 
given instant (tn) is compared with the image captured at the preceding instant (tn-1) and so on until all 
images are processed. Two different motility measurements were calculated. First, a precursor metric, 
“AdjustedRandIndex” is calculated by comparing worm objects identified on images captured at times tn 
and tn-1 with CellProfiler’s  Overlap module. This measure ranges from 0 to 1, with 1 meaning two objects 
are perfectly aligned (no movement). Hence, we created an “Overlap” mobility score, which is directly 
proportional to the amount of movement, by subtracting 1-“AdjustedRandIndex”. Another motility 
measure, “DiffWorms”, is the mean pixel intensity of the image calculated from the absolute difference 
of the parasite images in tn-1 and tn. The higher the DiffWorms score higher is the parasite mobility 
measured. Both measures are iteratively taken for the 99 image pairs and scores per well are calculated by 
averaging over all measurements.   
Statistical Analysis 
All statistical analysis and graphs were performed using GraphPad Prism version 5.00 for Windows 
(GraphPad Software, La Jolla California USA, www.graphpad.com). 
Ethics statement 
Animals were maintained and experiments carried out in accordance with the Institutional Ethics 
Committee for Laboratory Animal Use at the Oswaldo Cruz Foundation (CEUA/FIOCRUZ, Brazil; 
license number, LW-78/12) or using the NC3Rs and ARRIVE guidelines under the United Kingdom 
Animal’s Scientific Procedures Act 1986 with approval from the London School of Hygiene and Tropical 
Medicine Ethics committee.  
Results and discussion 
Hologram length and fragment size and distinction can affect the quality of HQSAR models [43,66]. 
In this work, various combinations of these parameters were tested. The final HQSAR models were 
obtained using combinations of different fragment distinctions (A, atoms; B, bonds; C, connectivity; H, 
hydrogen; DA, donor and acceptors of hydrogen bonds), fragment size (2-5, 3-6, 4-7, 5-8, 6-9, 7-10 atoms) 
and hologram length (53-401). 
Two compounds were identified as outliers (compounds 4 and 6, Table 1). These compounds presented 
residual values higher than two times the standard deviation in models containing all compounds of the 
dataset with the standard fragment size (4-7 atoms) and various combinations of fragment distinctions. 
Besides presenting high residue values, compounds 4 and 6 have unique structural features that are not 
observed in the other molecules of the dataset, i.e., the presence of aldehyde and amide functional groups. 
Although the measures of internal consistence (q2 and r2) are important parameters for the evaluation 
of QSAR models, in some cases they do not reflect the external predictivity of the models [67]. Thus, in 
this study, all QSAR models were validated using the external predictivity parameters (Q2ext, rm
2
(average) 
and rm
2
(delta)),  calculated after the prediction of biological activity of the test set compounds, which were 
completely excluded from models generation. 
The three best HQSAR models are presented in Table S1 (Supplementary Material). They have similar 
statistical characteristics but model 2 showed a slight superiority when evaluated the external set. The best 
HQSAR model was obtained using the fragment distinction A/DA (Table 2). The predicted activity (pIC50) 
for the test set compounds using this model (Table S2, Supplementary Material) indicated that only two 
compounds had their predicted values greater than the standard deviation of residuals, indicating a good 
predictive capacity of the model. The plot of the experimental versus predicted biological activity of the 
best HQSAR model is displayed in Supplementary Materials (Figure S1A). 
Table 2. Statistical characteristics for the best individual QSAR models obtained. 
 
 
 
 
 
 
 
 
 
 
 
q2LOO, leave-one-out cross-validated correlation coefficient; q
2
LMO, leave-many-out cross-validated correlation coefficient; r
2, noncross-validated correlation 
coefficient; N, optimal number of latent variables in PLS analysis; Q2ext, correlation coefficient of prediction;  rm
2
(average) and rm
2
(delta), variants of the modified 
r2. 
 
Besides predicting the biological activity of untested compounds, HQSAR models also give 
information regarding the relationships between the structural fragments and the biological activity, which 
can be visualized through the contribution maps. These maps indicate the individual contribution of each 
atom or fragment for the activity by color-coded schemes. Colors around red spectrum (orange, red orange 
and red) indicate negative contribution, while colors around green (yellow, green blue, green) indicate 
positive contribution to biological activity. The contribution maps for the most (33) and the less (2) potent 
compounds of our data set are presented in Figure 2. 
The contribution map for the most potent inhibitor of the dataset (33, Figure 2) suggests that the 
oxygen atom (O11) from carbonyl group has positive contribution for the biological activity. 
Model q
2
LOO q2LMO r2 N Q2ext rm2(average) rm2(delta) 
HQSAR 0.61 0.57 0.85 4 0.94 0.88 0.02 
CoMFA-model I 0.71 0.66 0.99 6 0.90 0.83 0.04 
CoMFA-model II 0.72 0.67 0.99 6 0.82 0.69 0.17 
CoMSIA-model I 0.51 0.48 0.99 6 0.95 0.88 0.06 
CoMSIA-model II 0.60 0.55 0.99 6 0.96 0.90 0.04 
Moreover, the furan ring is important for the biological activity since the O 17 has a positive 
contribution for activity. The carbon atoms C10, C13 and C14 also have positive contribution to the 
biological activity. Despite the fragments in green and yellow, the contribution map for the less 
potent inhibitor (2) suggests that the hydrogen atom attached to the carbon atom C12 negatively 
contribute to biological activity. The absence of the two carbonyl groups and furan rings in 
compound 2 suggests that these groups may play a critical role in SmTGR inhibition, because the 
activity decreased three logarithmic units in comparison to compound 33. 
 Previous study carried out by Gasco and co-workers [68] indicated that the oxadiazoles are 
capable of releasing nitric oxide in solution containing thiols by nucleophilic attack in C3 and C4 
carbon atoms. Because SmTGR has a selenocysteine (Sec) residue in the C-terminal end, the 
oxadiazoles may undergo nucleophilic attack mainly by this residue due to its superior reactivity in 
comparison to cysteine. The resulting nitric oxide release may be the reason for the antiparasitic 
activity described for these compounds [38]. The presence of the carbonyl group in the most potent 
inhibitors of the dataset suggests an important role of this group, which behaves as a linker that 
favors the nucleophilic attack in C3 and C4 atoms. 
 
 
Figure 2.  HQSAR contribution maps for the most (A, 33) and less (B, 2) potent SmTGR inhibitors. The 1,2,5-
oxadiazole ring is highlighted in blue, which is the maximal common substructure. 
 
In CoMFA and CoMSIA studies, the calculation of electrostatic descriptors depends on the 
assignment of partial atomic charges of the compounds. Therefore, the charge assignment method 
is critical to the success and may affect the quality of the developed models [24]. Furthermore, the 
contour maps may have some differences depending on the method used for partial atomic charges 
assignment [69,70]. Two different charge assignment methods were tested in this study, the 
empirical method Gasteiger-Hückel,[46,47] and the semi-empirical AM1-BCC charges [48,49]. 
Another crucial aspect in 3D-QSAR studies is the structural alignment, which is used to represent 
the probable bioactive conformation of the compounds. The quality of the 3D-QSAR models can be 
directly affected by the structural alignment [71]. Therefore, two ligand-based alignment hypotheses 
were tested, the shape-based alignment using ROCS software v.3.2.1.4 [51,52] and the 
morphological similarity alignment, implemented in Surflex-Sim, available at SYBYL-X v.1.2 
platform [42]. The data set was aligned using the two schemes, displayed in Figure 3. In alignment 
1, the best conformer of each molecule, after superposition, was classified according to 
TanimotoCombo score function. TanimotoCombo is a combination of the functions ShapeTanimoto, 
which compares the molecules according to the best molecular volume superposition, and 
ColorTanimoto which is related to the appropriate superposition of groups with certain properties 
like hydrogen bond donors and acceptors, hydrophobic, cation, anion and rings [52]. In alignment 
2, no previous conformers were generated since Surflex-Sim has fast techniques to generate poses. 
Additionally, a morphological similarity function is used to align the molecules. This function is 
defined as a Gaussian function of the distances of two molecules to observation points of a grid 
[72]. 
 Figure 3. Molecular alignment used in 3D-QSAR studies. (A) Shape-based alignment performed in ROCS; (B) 
Surflex-Sim alignment which uses a morphological similarity function. 
In 3D-QSAR, similarly to HQSAR, compounds 4 and 6 were identified as outliers, the same identified 
in HQSAR modeling. The outlier detection was performed using a CoMFA model generated with all 
compounds of the dataset and default grid spacing of 2.0 Å. The compounds 4 and 6 were identified as 
outliers, since their calculated residues were near or higher than two times the standard deviation of 
residues. 
CoMFA and CoMSIA models were investigated by PLS analysis, using the full cross -validated 
r2 (q2) leave-one-out (LOO) method. The leave-many-out (LMO) method was used to evaluate the 
stability of the best models. To evaluate the 3D-QSAR models predictive power, the final models 
were externally validated with the same test set of compounds. The biological activity was predicted 
for the test set molecules, and the Q2ext, rm
2
(average) and rm
2
(delta) were calculated. The full results of 
the best CoMFA and CoMSIA models are displayed in Supplementary Materials (Tables S3 and S4, 
respectively). 
The two best CoMFA models presented good internal consistence and high external predictivity 
(Table 2). The statistical results for the external validation (Q2ext, rm
2
(average) and rm
2
(delta)) were within 
the recommended values for predictive models [73]. The models generated using the AM1-BCC 
charges and ROCS alignment (Models I and II) showed superior performance in comparison with 
those generated using Gasteiger-Hückel charges and Surflex-Sim alignment (Table 2 and Table S3, 
Supplementary Material). 
The best CoMSIA models were obtained using the steric, electrostatic, hydrophobic and H-bond 
acceptor fields (Table S4, Supplementary Material). The two best CoMSIA models were obtained 
using ROCS alignment, one using Gasteiger-Hückel charges (Model I, Table 2) and the other using 
AM1-BCC charges (Model II, Table 2). These two models have similar results for internal validation 
and external predictivity. The differences between the two best CoMSIA models can be better 
visualized in the prediction of the activity of test set compounds (Table S2, Supplementary 
Material). The graphic results for the experimental versus predicted activities of both compound 
sets (training and test sets) are displayed in Figure S1B and S1C (Supplementary Material). 
The best CoMFA and CoMSIA models were used to generate contour maps. These maps indicate 
regions where certain types of interactions are favorable or unfavorable for biological activity [74]. 
The interpretation of contour maps is useful to guide the design of new potent inhibitors of SmTGR. 
CoMFA and CoMSIA contour maps were generated using the STDEV*COEFF field type and the 
function Contour by actual. Figure 4 shows contour maps obtained from (A) CoMFA steric 
(green/yellow) and (B) electrostatic (red/blue) fields; (C–F) CoMSIA steric (green/yellow), 
electrostatic (red/blue), hydrophobic (yellow/gray) and hydrogen bond acceptor (purple/magenta) 
fields with the most potent compound of the data set (33). 
 The steric contour map of the best CoMFA model (Figure 4A) shows green contours surrounding 
the furan ring of the compound (33), indicating that bulky substituents could be favorable to biological 
activity. Figure 4B shows red regions near the oxygen atoms O12 and O11 of the carbonyl groups, where 
substitution for electronegative groups can favor the biological activity. Furthermore, this map shows blue 
regions surrounding the carbon atoms of the furan rings, indicating that electronegative substituents at the 
furan rings are unfavorable. This map indicates that the carbonyl group represented by C7 and O12 atoms 
is important for biological activity. For the CoMFA and CoMSIA models, steric and electrostatic 
contribution maps were similar. The steric contour map of the best CoMSIA (Figure 4C) model also 
indicates that bulky groups in the region near the furan ring are favorable to biological activity. The 
electrostatic map (Figure 4D) indicates that electronegative groups in the region of the oxygen atoms of 
the carbonyl groups (O12 and O11) are favorable. Furthermore, electropositive groups in the region near 
the carbon atom C7 are favorable. In addition, the electrostatic CoMSIA map indicates that electronegative 
groups near the oxygen atom O17 of the furan ring are favorable to biological activity. The hydrophobic 
contour map (Figure 4E) shows two gray contours near the oxygen atoms of the carbonyl groups (O12 
and O11), indicating that hydrophobic groups are unfavorable in this region. Figure 4F shows a purple 
region near the oxygen atoms of the carbonyl groups (O12 and O11), suggesting that hydrogen bond 
acceptors groups in this region are favorable, whereas in regions near the two furan rings there are magenta 
contours, indicating that substitution for hydrogen bond acceptors is unfavorable to biological activity. 
 
Figure 4. CoMFA and CoMSIA countour maps. CoMFA steric and electrostatic (A-B) and CoMSIA steric, 
electrostatic, hydrophobic and H-bond acceptor (C-F) contour maps surrounding the most potent inhibitor 
(33). Steric fields: green contours indicate region where bulky groups are favorable for biological ac tivity; 
electrostatic fields: red contours indicate regions where electronegative groups are favorable to biological 
activity and blue contours indicate regions where electronegative groups are unfavorable; Hydrophobic 
fields: yellow contours indicate regions where hydrophobic groups are favorable and gray contours indicate 
regions where these groups are unfavorable; H-bond acceptor fields: purple contours indicate regions where 
hydrogen bond acceptors are favorable for biological activity and magenta contours indicate regions where 
hydrogen bond acceptors are unfavorable. 
Four different consensus models were obtained using different combinations of the best 2D- and 3D-
QSAR models (Table 3). The external validation of consensus models was performed using the same test 
set and metrics used in individual models. However, as observed in Table 3, the metrics Q2ext, rm
2
(average) 
and rm
2
(delta) presented similar results between models. Thus, three additional metrics were calculated for 
consensus modeling: root mean square error of calibration (RMSEC), root mean square error of prediction 
(RMSEP) and Durbin-Watson Test. The RMSEC is a measure of goodness of fit, while RMSEP is used 
to measure the difference between experimental results and predictions obtained by the model. These 
metrics are described elsewhere [56,57]. The Durbin-Watson Test (d) is used to evaluate the 
autocorrelation of residues [58–60]. A value of d equal or near 2 indicates no autocorrelation between 
residues. Values of d < 2 indicate that residues have a negative autocorrelation, i.e. residues have very 
different values. Values of d > 2 indicate a positive autocorrelation between residues. Model 4 (Table 3) 
was selected as the best consensus model because it had good performance and unites the characteristics 
of the three QSAR approaches explored. 
Table 3. Statistical characteristics for the consensus QSAR models.   
The best consensus model is highlighted in bold font. RMSEC, root mean square error of calibration; RMSEP, root mean square error of prediction; Q2ext, 
correlation coefficient of prediction; rm
2
(average) and rm
2
(delta), variants of the modified r
2; d, Durbin-Watson Test. 
 
 
The best consensus model was selected to perform a virtual screening of new potential SmTGR 
inhibitors. Firstly, a similarity search on the ChemBridge database [61] identified 80 compounds with at 
least TC≥0.6 similarity with compound 33. Additionally, 377 compounds containing the oxadiazole ring 
(common substructure) were identified. Duplicates and compounds already used to derive the QSAR 
models were excluded. Then, model 4 was used to predict the SmTGR inhibitory activity of remaining 
Model Models RMSEC RMSEP Q2ext rm2(average) rm2(delta) d 
1 HQSAR + CoMFA 0.16 0.16 0.96 0.92 0.01 1.44 
2 HQSAR + CoMSIA 0.16 0.12 0.98 0.93 0.03 1.41 
3 CoMFA + CoMSIA 0.04 0.18 0.95 0.91 0.05 2.02 
4 HQSAR + CoMFA + CoMSIA 0.11 0.14 0.97 0.93 0.04 1.41 
194 compounds. The consensus prediction of the biological activity was calculated using the arithmetic 
mean of the predictions from individual CoMFA and CoMSIA models (Table S5, Supplementary 
Material) shows the pIC50 prediction of each individual model as well as the consensus model.  
Poor pharmacokinetic properties are important causes of costly late-stage failures in drug development 
[75]. Our laboratory has been working to overcome or reduce these failures using in silico tools for early 
prediction and optimization of ADME properties, such as Caco-2 cell permeability, blood-brain barrier 
penetration (BBBP), hERG inhibition, CYP3A4 inhibition and water solubility. Five in-house highly-
predictive models were developed using large datasets of diverse compounds to cover the chemical space 
for the prediction of new compounds and are described elsewhere [26,27]. Table 4 shows the structure, 
consensus predicted potency against SmTGR (IC50 in M), and some predicted ADME properties of the 
ten new potential SmTGR inhibitors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Chemical structures, predicted potency against SmTGR and some calculated ADME properties of the lead 
compound (33) and the virtual hits. 
a IC50 prediction by the best consensus model. b Calculated octanol/water partition coefficient using RDKit 2.4.0. 
 
From Table 4 we can see that ten compounds selected as virtual hits presented high predicted 
potency against SmTGR, using the consensus QSAR model. Moreover, the selected hits were predicted to 
present favorable ADME properties and did not show any potential of being hERG blocker or CYP3A4 
inhibitors. These compounds were selected for subsequent in vitro biological evaluation against 
Cpd Structure 
IC50 pred 
a
 
(M) 
clogP b Caco2 BBBP 
Water 
Solubility 
(logS) 
CYP3A4 
Inhibition 
hERG 
inhibition 
33* 
 
 
0.04 
0.96 Moderate-poor BBB+ -1.91 Non-Inhibitor Non-blocker 
LabMol-13 
 
 
0.23 
5.10 Moderate-poor BBB+ -2.20 Non-Inhibitor Non-blocker 
LabMol-14 
 
 
0.03 
-0.85 Moderate-poor BBB+ -1.86 Non-Inhibitor Non-blocker 
LabMol-15 
 
 
1.23 
-1.41 Moderate-poor BBB+ -2.47 Non-Inhibitor Weak blocker 
LabMol-16 
 
 
0.06 
-2.37 Moderate-poor BBB+ -2.07 Non-Inhibitor Non-blocker 
LabMol-17 
 
 
2.40 
-0.20 Moderate-poor BBB+ -1.75 Non-Inhibitor Non-blocker 
LabMol-18 
 
 
1.54 
-0.58 Moderate-poor BBB+ -2.94 Non-Inhibitor Non-blocker 
LabMol-19 
 
 
0.51 
-0.37 Moderate-poor BBB+ -2.37 Non-Inhibitor Non-blocker 
LabMol-20 
 
 
1.00 
-0.93 Moderate-poor BBB+ -1.98 Non-Inhibitor Non-blocker 
LabMol-21 
 
 
1.12 
-1.11 Moderate-poor BBB+ -2.17 Non-Inhibitor Non-blocker 
LabMol-22 
 
 
0.89 
-1.72 Moderate-poor BBB+ -2.47 Non-Inhibitor Weak blocker 
schistosomula and adult S. mansoni worms. From them, two compounds (LabMol-17 and LabMol-19) 
were confirmed experimentally as new hits against Schistosoma mansoni.  
Motility and phenotypic scores of the two hit compounds at 10 µM along with the negative (DMSO 
0.625%) and positive controls (PZQ or OLT 10 M) are shown in Table 5. The phenotypic and mobility 
scores calculated by the Bayesian model for both hits indicate their effects on schistosomula are equivalent 
or even more pronounced than produced by the reference drugs PZQ and OLT.  EC50 values could be 
calculated from dose-response curves using either motility score (LabMol-19 EC50 1.00 ± 0.11 M) or 
phenotype score as the response (LabMol-17 EC50: 4.76 ± 1.15 M). The motility EC50 value determined 
for LabMol-19 was comparable to PZQ (EC50: 2.2 µM) [76]. 
Table 5 – Motility and phenotype adjusted index values for S. mansoni schistosomula exposed for 48h to 
hit compounds or standard drugs at 10 µM. 
Compound 
Motility 
adjusted index  
(mean ± SD) 
Phenotype 
adjusted index  
(mean ± SD) 
Motility image Phenotype image 
Control (DMSO 0.625%) 
  
LabMol-17 
-0.95 ± 0.01 
 
-0.43 ± 0.11 
 
  
LabMol-19 
-0.95 ± 0.01 
 
-0.63 ± 0.02 
 
  
PZQ -0.48 ± 0.04 -0.17 ± 0.02 
  
OLT -0.90 ± 0.04 -0.34 ± 0.07 
  
The outlines showed in motility images represent the position of each parasite over 5 timepoints (11s interval).
  
Furthermore, the Bayesian model was able to classify the phenotype induced by both hit 
compounds as OLT-like indicating that the phenotype induced by these compounds was closest to OLT 
in comparison to the other modelled schistosomacides (PZQ, dihydroartemisinin, methylclonazepam, 
Ro15-5458, oxamniquine). This result is consistent with the fact that both LabMol-17 and LabMol-19 are 
potential SmTGR inhibitors, an enzyme involved in ROS detoxification in the S. mansoni, similar to the 
OLT mechanism of action which is also thought to interfere with the parasite’s redox defense system [77]. 
Compounds active on schistosomula were then tested on S. mansoni adult worms in vitro. Chemicals were 
assayed by a new methodology that utilizes HCS technology to automatically score changes on parasite 
motility. Besides avoiding human bias, this quantitative method is more robust and sensitive to subtle 
changes in parasite movement than the standard assay using manual microscopic visualization [78]. 
Figures 5 and 6 shows percent motilities of  male and female worms, respectively, measured after exposure 
to drugs at 10 µM for up to 72h incubation time.     
 
  
 
Figure 5. The effect of compounds on male adult worm motility as analyzed by HCS analysis for 0 -
72hrs. PZQ, LabMol-17 and LabMol-19 were screened at 10 µM and DMSO at an equivalent % 
concentration. The percentage motility values were determined immediately (A), 24hrs (B), 48hrs (C) or at 
72 hrs (D) by comparison to the average motility of the worms before compound addition. CTL - DMSO 
0.02%, PZQ - Praziquantel. Statistical significance (* = p<0.05) was calculated by One-way ANOVA 
analysis followed by Tuckey´s post-hoc test.       
 
  
 
Figure 6. The effect of compound on female adult worm motility as analyzed by HCS analysis for 0 -
72hrs. PZQ, LabMol-17 and LabMol-19 were screened at 10 µM and DMSO at an equivalent % 
concentration. The percentage motility values were determined immediately (A), 24hrs (B), 48hrs (C) or at 
72 hrs (D) by comparison to the average motility of the worms before compound addition. CTL - DMSO 
0.02%, PZQ - Praziquantel. Statistical significance (* = p<0.05) was calculated by One-way ANOVA 
analysis followed by Tuckey´s post-hoc test.       
 
Like PZQ, both LabMol-17 and LabMol-19 were more active on male worms. LabMol-17 
was the most active hit, reducing male worm motility up to five times compared to untreated control 
worms. Significant reduction (p<0.05) of male worm motility was observed immediately after 
addition of the drugs to the microplate well and in the case of LabMol-17 peaked after 48h 
incubation. Effects on female worms were less pronounced. A discernible, although not statistically 
  
significant, trend could still be observed for LabMol-17 after 24h and 48h of drug exposure. 
Interestingly, although not statistically significant for the whole treatment group, LabMol-19 
induced augmented motility in at least half of the female worms in the group on exposure times up 
to 48h.  Further experiments will elucidate if this different behavior on drug sensitivity between 
male and female worms may be due to different expression patterns of SmTGR or other cause. 
  It is interesting to note that the two experimentally validated hits, LabMol-17 and LabMol-19, 
are dissimilar from the most potent compound (33) in the training set (Tc of 0.60 and 0.63, respectively 
(Table S5, Supplementary Material)). More interestingly, the most active hit, LabMol-17, is very 
dissimilar from the current schistosomicidal drug, PZQ (Tc = 0.07) and oltipraz (Tc = 0.08), and also from 
other known drugs (Figure 7).  
 
 
Figure 7. Radial plots for similarity of LabMol-17 with known schistosomicidal drugs and known 
SmTGR hits. The central node represents the target compound surrounded by known schistosomicidal drugs 
(left-hand side) and known SmTGR hits from a HTS screen retrieved from PubChem BioAssay (AID: 
485364) (right-hand side). The similarity was calculated using Tanimoto coefficient (Tc) using Morgan 
(ECFP4-like) fingerprints [79]. 
 
  
 
Moreover, we have also analyzed the similarity between LabMol-17 and known SmTGR hits 
discovered in a HTS screening (PubChem BioAssay, AID: 485364). As we can see from Figure 7, the 
Tanimoto coefficient values are in the range between 0 and 0.3, showing that the compounds are 
very dissimilar, and therefore, LabMol-17 has proved to represent a new chemical scaffold against 
S. mansoni. 
Because of this structural difference and high activity against schistosomula and adult worms, the 
two hit compounds (LabMol-17 and LabMol-19) are promising as new potential SmTGR inhibitors 
representing new not yet explored chemical scaffolds. 
 
Conclusion 
We succeed to develop robust and externally predictive consensus model including 2D (HQSAR) and 
3D QSAR models (CoMFA and CoMSIA). Developed consensus model was used for virtual screening of 
ChemBridge database. We identified ten new potential SmTGR inhibitors. High activity of two of these 
hits (LabMol-17 and LabMol-19) containing new scaffolds and pretty structurally dissimilar from known 
antishistosomal agents was validated experimentally against S. mansoni on both schistosomula and adult 
worms in vitro. We are going to conduct additional experimental validation and structural modification, 
if needed, of these compounds to develop new schistosomicidal agents on their base. 
 
Future perspective 
Despite urgent need in finding a new treatment for schistosomiasis and some success that was 
achieved recently, there is still a long way to go to defeat this NTD. There are multiple potential ways of 
battling schistosomiasis. The first one is the development a vaccine. Nowadays, there are ongoing clinical 
trials for several vaccines against various Schistosoma strains [80]. Thus, a vaccine against Schistosoma 
haematobium is under Phase III of clinical trials in Senegal and Niger and two vaccines against 
  
Schistosoma mansoni are under Phase I of clinical trials in US and Brazil [80]. However, despite this, 
there are numerous challenges in vaccine development related to the antigen discovery, product 
development, and the preclinical and clinical testing stages. For instance, reverse vaccinology approaches 
that work well for small bacterial genomes have not yet been successful for eukaryotic parasites because 
of the greater complexity of the parasite genome and the requirement to employ eukaryotic expression 
systems to reliably produce soluble and properly folded antigens. However, scientific challenges are not 
the major obstacle for the development of new vaccines; socioeconomic reasons are the real bottleneck 
there. For instance, there are no clear ways to make a vaccine, even potent and effective, available to those 
who need it most – poor people in South America, Africa, and Asia.                                                                       
Another way of battling schistosomiasis is development of new small molecule drug. Obviously, 
this drug should be active against all the different strains of Schistosoma. Thus, this drug has to be 
promiscuous enough to cover a variety of strains and selective enough not to hit other targets in the human 
organism, because the interaction with some of them could lead to strong undesirable side effects. This is 
still very possible way, although, like in case of vaccines, similar socioeconomic challenges could prevent 
the development and especially targeted distribution of such drug. In other words, even if developed, such 
a drug could cost that much that the price could be affordable only by a small richer part of population 
and still will be unavailable to poorer part, which suffer from schistosomiasis the most. Another possibility 
is the combination therapy, which could help to overcome solving scientific bottlenecks such as drug 
resistance phenomenon, toxicity, etc. In the same way, combinatorial therapy could cause undesired drug-
drug interactions. All social and economic problems of monotherapy will also remain to combined 
treatment. One of the solutions to decrease the economical burden is the use of computational techniques 
for targeted design of new anti-schistosomiasis agents that will decrease both the time and the money 
spent to develop new drug. Expected future development of combined therapy will promote development 
of reliable computational tools for handling and analyzing mixtures [81]. In addition, these approaches 
should take into account both synergistic and antagonistic effects [82]. We strongly believe that in future 
  
battling neglected tropical diseases will include some other approaches unknown and even unpredictable 
now and that these approaches will help to overcome not only scientific but also socioeconomic 
challenges. 
Concluding this section we would like to point out that our new adult worm HCS platform was 
instrumental for the reliable quantification of drug-induced alterations in parasite motility, however some 
work will be done in our group to further extend this technology to score adult worm phenotypes as it is 
already possible for schistosomula. We are also going to additionally validate the activity of hit 
compounds identified in this study by different experiments. Structural modification could also be done if 
needed to improve ADMET properties of designed compounds.  
Executive summary 
 2D- and 3D- QSAR methods were used to build highly predictive consensus models. 
 A QSAR-based virtual screening identified ten new potential inhibitors of SmTGR. 
 A new high-content screening platform for quantification of worm motility was validated. 
 In vitro activity against schistosomules and adult worms for two compounds was confirmed 
experimentally. 
 LabMol-17 and LabMol 19 will be subjects for additional experimental testing and structural 
modification to design new schistosomicidal drugs. 
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